Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

DNL919

Small molecule · developed by Denali Therapeutics

Phase 1 Most advanced trial (none active)
DNLI Developer
1 Registered trials

What is DNL919?

DNL919 is a drug name for which the available source material provides no details on its class, target or mechanism. It has been studied in healthy participants.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Developer
Denali Therapeutics Inc. (DNLI)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05450549 Phase 1 Healthy Participant Completed DNLI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Participant

More from Denali Therapeutics

Tividenofusp Alfa FDA approved DNL126 Phase 1/2 DNL201 Phase 1 DNL343 Phase 2/3 DNL593 Phase 1/2 DNL628 Phase 1 DNL747 Phase 1 DNL921 Phase 1 DNL952 Phase 1

Follow DNLI, the company behind DNL919

See DNLI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DNLI catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.